Abstract The COX-2 product prostaglandin E 2 (PGE 2 ) contributes to the high metastatic capacity of breast tumors. Our published data indicate that inhibiting either PGE 2 production or PGE 2 -mediated signaling through the PGE 2 receptor EP4 reduces metastasis by a mechanism that requires natural killer (NK) cells. It is known that NK cell function is compromised by PGE 2 , but very little is known about the mechanism by which PGE 2 affects NK effector activity. We now report the direct effects of PGE 2 on the NK cell. Endogenous murine splenic NK cells express all four PGE 2 receptors (EP1-4). We examined the role of EP receptors in three NK cell functions: migration, cytotoxicity, and cytokine release. Like PGE 2 , the EP4 agonist PGE 1 -OH blocked NK cell migration to FBS and to four chemokines (ITAC, MIP-1a, SDF-1a, and CCL21). The EP2 agonist, Butaprost, inhibited migration to specific chemokines but not in response to FBS. In contrast to the inhibitory actions of PGE 2 , the EP1/EP3 agonist Sulprostone increased migration. Unlike the opposing effects of EP4 vs. EP1/EP3 on migration, agonists of each EP receptor were uniformly inhibiting to NK-mediated cytotoxicity. The EP4 agonist, PGE 1 -OH, inhibited IFNc production from NK cells. Agonists for EP1, EP2, and EP3
Introduction
Natural killer (NK) cells are a subset of lymphocytes that participate in innate immunity with diverse functional activities including cytotoxicity and the capacity to produce cytokines and chemokines. NK cells are involved in different effector functions as part of an early defense system. These functions are regulated by the interplay between inhibitory and activating receptor signaling that control the response of NK cells when they encounter a potential target cell. One such target cell is the tumor cell, many of which produce high prostaglandin E 2 (PGE 2 ) levels due to elevated cyclooxygenase-2 (COX-2) activity. PGE 2 is a small lipid molecule that regulates numerous processes from reproduction to neuronal and metabolic functions. These effects are mediated through a family of G-protein-coupled receptors identified as EP1, EP2, EP3, and EP4. PGE 2 is a potent regulator of inflammation as well as innate and adaptive immune responses and contributes to immune evasion in malignancy. It is known that PGE 2 down regulates IL2-activated LAK cell cytotoxicity through EP2 receptors [1, 2] . LAK cells (activated NK cells) are generated from adherent splenocytes cultured in IL2. In a study by Su et al. [1] , LAK cells were treated with various EP receptor agonists and antagonists to identify which were involved in the immunosuppressive effects of PGE 2 . They show that an EP2 agonist significantly inhibits LAK cytotoxicity and that the inhibitory effects of PGE 2 can be blocked using an EP2 antagonist. In contrast, neither an EP1/EP3 agonist nor EP1 or EP4 antagonists modulate LAK cell cytolytic activity. Thus, PGE 2 -mediated inhibition of LAK cytotoxic activity is through the EP2, but not the EP1, EP3, or EP4 receptors. The role of individual EP receptors in regulating activities of endogenous, resident splenic NK cells has not been investigated. Therefore, this study has identified the EP receptors that control three NK cell functions in endogenous splenic NK cells: cytotoxicity, cytokine secretion, and migration. PGE 2 contributes to malignant behavior in breast and other malignancies. Despite the fact that preclinical studies indicate that targeting PGE 2 synthesis through COX-2 inhibition is promising, the safety of COX-2 inhibitors has drawn some concern. Therefore, alternative approaches to target the COX-2 pathway are being sought. Our laboratory initially showed that COX inhibitors or EP4 antagonists could limit tumor growth and metastasis. Further analysis revealed that COX inhibitors and EP4 receptor antagonism contribute to NK functions critical to the control of metastatic disease [3, 4] . In vivo, NK cells were necessary for the therapeutic effects of COX inhibitors. Further, mammary tumor cells treated with COX inhibitors were more sensitive to NK-mediated lysis. Moreover, expression of inhibitory ligands for NK cells were decreased and stimulatory ligands were increased by treatment with COX inhibitors or EP4 receptor antagonists. These studies suggest that EP4, expressed on malignant cells, is a potential therapeutic target. Little was known, however, regarding the role of EP4, or any other EP expressed on the NK cell, in regulating antitumor responses.
We have now characterized the role of individual EP receptors on endogenous NK functions and show that EP4 expressed in endogenous NK cells and to a lesser extent EP2 contribute to the mechanisms by which PGE 2 suppresses critical NK cell functions.
Materials and methods

Cell lines and mice
The Yac-1 murine T lymphoma cell line that is sensitive to NK-mediated cytolysis was used. Yac-1 cells were cultured at 37°C in 5% CO 2 in RPMI 1640 plus media that contained 10 mM HEPES, 1 mM sodium pyruvate, 4,500 mg/L glucose, 1,500 mg/L sodium bicarbonate and supplemented with 10% FBS. Immune-competent Balb/ cByJ female mice were purchased from Jackson Laboratory (Bar Harbor, ME). Experiments were performed according to IACUC approved protocols.
Enriched NK cell isolation
An untouched population of NK cells from spleen cell suspension was isolated following manufacturer's protocol using the NK Cell Isolation Kit (Miltenyi Biotec Inc., Auburn, CA). The entire effluent fraction collected represented the enriched NK cells identified as DX5
? CD3 -cells.
Flow cytometry
For EP receptor studies, enriched NK cells from normal mice were reacted with monoclonal mouse DX5 (CD49b) and CD3e (BD PharMingen, San Diego, CA) conjugated antibodies. The cells were then stained with an unconjugated primary rabbit polyclonal antibody directed to EP1, EP2, EP3, or EP4 (Cayman Chemical Company, Ann Arbor, MI) followed by fluorochrome-conjugated secondary goat anti-rabbit and fixation in 4% paraformaldehyde for 15 min with final preparation in PBS. All flow cytometry samples were processed at the Flow Cytometry Shared Services at the University of Maryland Greenebaum Cancer Center.
RT-PCR
RNA was extracted from enriched NK cells using NucleoSpin Ò RNA II kit (Macherey-Nagel, Bethlehem, PA) and reverse-transcribed and amplified using EP-specific or GAPDH control primers. The reaction mixture was then placed in a preheated (94°C) thermal cycler where the initial denaturing step was performed for 2 min followed by 36 cycles of denature 94°C for 1 min, annealing at 56°C for 40 s, and extension at 72°C for 50 s. Upon completion, a final extension was performed at 72°C for 2 min and samples held at 4°C.
EP receptor reagents NK cell EP receptors were pharmacologically targeted using selective agonists and antagonists from Cayman Chemical. SC19220 and SC52089 were used to competitively antagonize the EP1 receptor. The EP1/EP2 receptor was antagonized using AH6809 and EP4 receptor was antagonized with AH23848 and GW627368X (GWX). To stimulate the receptors, PGE 2 (EP1-4), Sulprostone (EP1/ EP3), Butaprost (EP2), and Prostaglandin E 1 Alcohol (PGE 1 -OH, EP4) were used as agonists.
cAMP EIA NK cells were either untreated, treated with vehicle control (DMSO), PGE 2 (0.1 lM, 1 lM, or 10 lM), or antagonists to specific EP receptors (AH23848, GWX, AH6809, SC19220, and SC51089). NK cells were treated for 30 min, and culture media was removed. NK cell pellets were lysed using reagent 1B provided in Amersham cAMP Biotrak Enzymeimmunoassay System (GE Healthcare, Piscataway, NJ) and the intracellular cAMP experiment was performed according to manufacturer's instructions.
Migration assay
The Chemo Tx Ò System (Neuro Probe, Gaithersburg, MD) and a 3-lm pore size were used to estimate migration. NK cells, at time 0, were treated with or without EP receptor agonists (PGE 2 , Butaprost, Sulprostone, and PGE 1 -OH) and the chemotactic response to FBS, ITAC, MIP-1a, SDF-1a, and CCL21 was assessed. Treated NK cells were pipetted onto the filter top and incubated at 37°C, 5% CO 2 for 3 h. After incubation, cells were gently washed from the top side of the framed filter. Migrated cells were labeled by the addition of Calcein AM. After 1-h incubation, the microplate was placed in a fluorescence reader (485 nm) to count migrated cells in the microplate wells. The results were calculated from a generated standard curve and data expressed as number of cells migrated.
NK cell-mediated cytotoxicity assay NK cell-mediated cytotoxicity was measured using the CytoTox 96 Ò Assay (Promega, Madison, WI), which quantitatively measures the release of the stable enzyme lactate dehydrogenase (LDH) upon cell lysis. NK cells were cultured with Yac-1 lymphoma targets at several effector/target (E:T) ratios: 2:1, 5:1, 10:1. NK cells were pretreated with various PGE 2 concentrations (1.0 and 10 lM), Butaprost (1.0 and 10 lM), Sulprostone (1.0 and 10 lM), or PGE 1 -OH (1.0 and 10.0 lM). After pretreatment with agonists, Yac-1 tumor targets were added and co-incubated for 18 h. The supernatant was harvested and transferred to the enzymatic assay plate where the Substrate Mix was added, and the reaction halted with Stop Solution and absorbance determined at 490 nm. To compute corrected absorbance values, the following formula was used to obtain percent cytotoxicity for each effector/ target cell ratio:
ELISA NK cells were pretreated with either vehicle control (DMSO) or agonists (PGE 2 , Butaprost, Sulprostone, PGE 1 -OH) for 30 min. At the end of 30 min, cells were stimulated with 1,000 U/mL of IL2 and incubated at 37°C, 5% CO 2 . At 18 h, cell culture-conditioned media was collected. Mouse IFNc ELISA Ready-SET-Go! Ò and Mouse TNFa ELISA Ready-SET-Go! Ò kits (eBioscience, San Diego, CA) were used to measure cytokines in cell condition media, and assays were performed according to the manufacturer's instructions.
Statistical analysis
The results are expressed as mean ± SE of at least n = 3. A one-way analysis of variance (ANOVA) was used to compare mean control groups (DMSO) and experimental groups. Overall test analysis was reported as significant at P value \ 0.05.
Results
Enriched populations of normal NK cells from Balb/cByJ female mice (6-10 weeks) were isolated from total spleen cells by negative selection using immunomagnetic beads. After selection, the purity of DX5
? CD3 -cells was confirmed by flow cytometry. Seventy-six percent of the isolated cells were identified as DX5
? CD3 -NK cells (Fig. 1a) . This enriched population was used in all experiments and referenced as normal endogenous NK cells.
Murine IL2-activated NK (LAK) cells were reported to express all four EP receptors [1] . To determine which EP receptors were expressed on normal endogenous NK cells, we examined the expression of EP receptors by flow cytometry. All four EP receptors were detected on the surface of endogenous NK cells (Fig. 1b) . Fifty-one percent of murine NK cells had detectable EP2. The EP1, EP3, and EP4 receptors were all expressed at similar levels; 29, 33, and 34 percent of cells were positive, respectively. RT-PCR analysis further confirmed the presence of mRNA for all four EP receptors (Fig. 1c) .
EP2 and EP4 receptors are G-protein-coupled receptors that upon activation elevate intracellular cAMP levels. If the reported inhibitory effects of PGE 2 on NK cells are mediated through EP2/EP4 signaling, PGE 2 treatment of NK cells should increase the intracellular cAMP levels in these cells. To test this, the intracellular cAMP levels of NK cells treated with vehicle control were compared with those of PGE 2 -treated NK cells. PGE 2 dose-dependent manner (Fig. 2a) . To identify which EP receptor mediated cAMP activation, specific EP receptor antagonists were added to block PGE 2 stimulation of cAMP. The EP1 antagonists SC19220 and SC51089, EP1/ EP2 antagonist AH6809, and EP4 antagonists AH23848 and GW627368X (GWX) were all utilized (Fig. 2b, c) . In the experiment shown in Fig. 2b , PGE 2 (1.0 lM) stimulated cAMP production by approximately 2.5-fold. The EP2 and EP4 antagonists alone did not significantly affect the basal cAMP levels. In the presence of PGE 2 , the EP2 antagonist (AH6809) or the EP4 antagonists (AH23848 or GWX) were able to significantly block the PGE 2 -mediated increase in cAMP (Fig. 2b) . Neither EP1 antagonist (SCI9220 or SC51089) was capable of reversing the elevation of cAMP in PGE 2 -treated NK cells (Fig. 2c) . These results indicate that PGE 2 induces adenylate cyclase in NK cells through the EP2 and EP4 receptors as reported in other cells. Whether PGE 2 affects the migration of NK cells was assessed. Migration of NK cells was determined by estimating the number of cells migrating through a porous membrane for 3 h. NK cells migrated across the membrane in the presence of four percent fetal bovine serum or the chemokines; ITAC, MIP1a, SDF-1a, or CCL21 all at 100nM. These chemokines were chosen because of their known ability to induce migration of resting NK cells [5] . Treatment with PGE 2 (1.0 or 10 lM) blocked migration of NK cells in response to each chemokine as well as to FBS (Fig. 3a) . PGE 2 inhibited migration by 35-71 percent. To identify which EP receptor is involved in PGE 2 -mediated inhibition of NK cell migration, NK cells were treated with EP receptor-specific agonists. Like PGE 2 , the EP4 agonist PGE 1 -OH blocked NK cell migration to each stimulant (Fig. 3b) . The EP2 agonist Butaprost did not significantly blunt migration to FBS, but significantly reduced the response to three chemokines tested (Fig. 3c) . In contrast to the inhibitory actions of PGE 2 , the EP1/EP3 agonist Sulprostone increased migration of NK cells regardless of the stimulant (Fig. 3c) . These data show that the ability of PGE 2 to inhibit migration is relevant to physiological chemotactic factors and always mimicked by activation of the EP4 receptor and, in the case of specific chemokines, by EP2. Conversely, activation of the EP1 and/or EP3 receptors promotes migration.
Cytotoxicity is a major function of NK cells; therefore, effects of PGE 2 on the cytotoxic capacity of NK cells were investigated. NK cells were pretreated with different concentrations of PGE 2 (0.01-10.0 lM) for 30 min before testing their capacity to lyse Yac-1 tumor targets. Cytolytic activity of endogenous NK cells ranges from 10 to 20 percent (Fig. 4a) . Preincubation with PGE 2 modestly inhibited NK-mediated cytotoxicity (Fig. 4a) . To determine which EP receptor mediated the inhibitory effect, NK cells were pretreated with EP receptor agonists and cytolytic activity was measured. Unlike migration, where only the EP4 and EP2 agonists mimicked PGE 2 inhibition, agonists of each of the four receptors were able to inhibit NK-mediated cytotoxicity (Fig. 4b-d) . 
To examine the effects of PGE 2 on the ability of NK cells to secrete cytokines, the effects of PGE 2 on the production of two type I cytokines (IFNc and TNFa) were examined. NK cells were pretreated with PGE 2 for 30 min, then stimulated with 1,000 U/mL of IL2 to induce cytokine production. Pretreatment with PGE 2 profoundly reduced the amount of IFNc produced by NK cells compared to control (Fig. 5a) . At 1.0 and 10.0 lM, PGE 2 inhibited IFNc production by 92 and 94 percent, respectively. To determine which EP receptor is involved in inhibition, NK cells were targeted with specific agonists. Inhibition of IFNc production by NK cells was observed when EP4 agonist PGE 1 -OH pretreated NK cells were stimulated with IL2 (Fig. 5a ). Eighty-eight and 85 percent inhibition of IFNc production at 1.0 and 10.0 lM concentrations of PGE 1 -OH, respectively, were observed compared to DMSOtreated cells. The agonists for the EP1, EP2, and EP3 receptors were not as efficient as either PGE 2 or an EP4 agonist at inhibiting IFNc production (Fig. 5b) . The EP2 agonist Butaprost at 1.0 lM inhibited IFNc production by 15%; eighty percent inhibition was achieved by Butaprost at 10.0 lM concentration. The EP1/EP3 agonist Sulprostone inhibited IFNc by only 10 and 28 percent at the 1.0 and 10.0 lM concentrations, respectively.
TNFa is secreted by NK cells, especially during tumorigenesis. Pretreatment with PGE 2 led to a 51-100 percent inhibition of TNFa secretion by NK cells in a dosedependent manner (Fig. 5c) . Inhibition of TNFa secretion was achieved by using all three EP receptor agonists. Stimulating the EP4 receptor with PGE 1 -OH yielded results that most resembled PGE 2 ( Fig. 5c ) with complete inhibition of TNFa secretion at both concentrations employed. The EP2 agonist Butaprost and the EP1/EP3 agonist Sulprostone also inhibited TNFa secretion but were less effective than PGE 2 or an EP4 agonist (Fig. 5d) .
Discussion
The ability of PGE 2 to regulate immune responses of T lymphocytes has long been recognized, but much less is known regarding the role of PGE 2 in mediating NK cell functions. In this study, we examined the effects of PGE 2 on normal murine NK cells and identified which EP receptors regulate NK cell functions. We showed that endogenous murine NK cells expressed all four EP receptors. An interesting question is whether the same NK cell expresses multiple EP receptors. This question has been technically challenging because all EP receptors are identified with rabbit polyclonal antibodies. Our preliminary results indicate that EP4-positive NK cells rarely express EP2. One recent report contradicted our findings reporting that NK cells from three human donors expressed simultaneously, the EP2, EP3, and EP4, but not EP1 receptors [6] . In addition to possible species differences, they cultured NK cells in IL2; our unpublished data show that IL2 activation of murine NK cells downregulates EP receptor expression.
Elevations in intracellular cAMP suppress innate immune functions of macrophages, monocytes, and neutrophils [7] . Early work in NK cells suggests an association between elevated cAMP and suppression of NK cell activity [8] . We also examined the effects of PGE 2 on cAMP activity. PGE 2 stimulated increased intracellular cAMP in a dose-dependent manner in NK cells. Based on the ability of EP2 or EP4 agonists to mimic the activities of PGE 2 , we concluded that the PGE 2 -mediated increase in cAMP was regulated through both EP2 and EP4 receptors. This was anticipated, since in other cells, the EP2 and EP4
receptors are both coupled to the Ga s subunit known to be involved in stimulating adenylyl cyclase [9] . The cAMP response was not linked to the EP1 receptor because an EP1 agonist did not affect cAMP levels. On other cells, the EP1 receptor is coupled to the Ga q subunit [9] . Upon PGE 2 stimulation, antagonists to the EP1 receptor will most likely block calcium mobilization. There were limitations with determining whether the EP3 receptor was involved in Relative to DMSO, *P \ 0.05 PGE 2 -stimulated adenylyl cyclase activity because there are no commercially available specific EP3 antagonists. However, based on our results and current knowledge that the EP3 receptor is coupled to the Ga i subunit, it is postulated that PGE 2 would not stimulate adenylyl cyclase through EP3 on NK cells. NK cells are one of the first immunological cells arriving at sites of injury or inflammation. To do so, the NK cell must respond to either soluble or surface bound signals that stimulate cell migration. Our studies show that PGE 2 inhibited NK cell migration to a broad spectrum of chemotactic signals through the EP4 and EP2 receptors. While we know that NK cell migration is negatively regulated through the EP4 receptor, the downstream events are not fully understood. One mechanism may be through cAMP as a second messenger. Although we found PGE 2 to inhibit migration through the EP4 receptor, in Langerhans cells, a type of dendritic cell in the epidermis, the EP4 receptor plays an important role in promoting, rather than inhibiting, migration [10] . This was confirmed using human monocyte-derived dendritic cells. Legler et al. [11] showed that PGE 2 induced migration of dendritic cells through the EP4 receptor. Since dendritic cells play a role in T cell activation, we postulate that PGE 2 may play a pro-migratory function in this setting allowing dendritic cells to come into proximity with T lymphocytes. Thus, the same EP4 receptor can promote or inhibit migration of different immune effector cells.
An interesting finding was that Sulprostone, an EP1/EP3 receptor agonist, actually increased migration to chemokines by 1.3-1.6-fold. The EP1/EP3-mediated increase in migration may be driven by EP1 stimulation of phospholipase C (PLC), which leads to downstream release of inositol 1,4,5-triphosphate (IP 3 ) and activation of protein kinase C (PKC). In T cells, migration across the vasculature is controlled by PKC [12] . Thus, all EP receptors are not uniformly suppressive to all NK cell functions. An opposing role for EP1 versus EP4 has also been described in tumor metastasis. We showed that EP4 promotes mammary tumor cell metastasis, but EP1 is a metastasis suppressor [3, 13, 14] . Because EP1 is a lower affinity receptor compared with EP2 and EP4, it is possible that pro-migratory responses are only elicited when tissue PGE 2 levels are very high.
Natural killer cells have been named for their ability to mediate cytotoxicity against transformed and infected cells. In the presence of PGE 2 , NK-mediated cytotoxicity against Yac-1 tumor targets is inhibited. Our laboratory has previously shown that the COX inhibitor indomethacin, which suppresses PGE 2 production, decreases expression of the inhibitory ligand MHC class I and increases activating ligands H60 and Rae-1 on mammary tumor cells [4] , unpublished data). Therefore, PGE 2 may inhibit NK-mediated cytotoxicity by allowing engagement of the inhibitory receptor Ly49 and preventing activation of the NKG2D receptor as a result of diminished H60 and Rae-1 levels. Three effector-to-target ratios were used: 2:1, 5:1, and 10:1. Data presented as percent NKmediated cytotoxicity ± SE and represents n of 3. Overall testing for main effect of PGE 2 inhibition P value \ 0.0001 Consistent with this hypothesis, Zeddou and colleagues [15] show that PGE 2 increases the percentage of cells expressing CD94/NKG2A, an inhibitory receptor, resulting in diminished cytolytic potential. Although that study examined T cells, it can be presumed that this mechanism could be relevant to NK cells.
Specific agonists of each EP receptor modestly inhibited cytotoxicity. In contrast, PGE 2 inhibited cytotoxicity in activated NK cells (LAK cells) only through the EP2 receptor [1] . In that study, LAK cells were treated with EP2 agonist (Butaprost), EP1/EP3 agonist (Sulprostone), and antagonists to the EP1 (SC19220), EP2 (AH6809), and EP4 (AH23848) receptors. Only Butaprost could inhibit cytotoxicity and the antagonist AH6809 blocked PGE 2 -mediated inhibition of cytotoxicity. Therefore, the authors concluded that the EP2 receptor, but not EP1, EP3, or EP4, was involved in the inhibitory signaling on LAK cells. While our data also implicate the EP2 receptor, we also show the EP1, EP3, and EP4 receptors are also involved in the regulation of cytotoxicity mediated by endogenous NK cells. We have observed that activated NK cells have a different EP receptor profile than endogenous NK cells (data not shown), which may lead to different signaling patterns in these two populations.
The ability of the EP1/EP3 receptor agonist Sulprostone to inhibit NK-mediated cytotoxicity was not predicted. Based on migration data, we predicted that Sulprostone treatment would increase NK-mediated cytotoxicity or have no effect on this function. FasL is a member of the tumor necrosis factor (TNF) superfamily that can trigger apoptotic cell death following receptor-ligand binding. O'Callaghan et al. [16] observed that PGE 2 increased FasL expression on colon tumor cells increasing cytotoxicity against Fas-sensitive Jurkat T cells. We hypothesize that Sulprostone is stimulating the EP1 receptor, which may play a role in increased Fas ligand (FasL) expression on tumor cells triggering apoptosis of the NK cell.
In addition to mediating cytotoxicity, NK cells play an important regulatory role in the immune response through production of cytokines. IFNc exerts antiproliferative, immunoregulatory, and proinflammatory activities and is thus important in host defense mechanisms. We show that 6 cells ± SE, n = 3. Relative to DMSO, EP receptor agonists (PGE 2 , PGE 1 -OH, Butaprost, and Sulprostone) *P \ 0.05, **P \ 0.01, ***P \ 0.001 pretreatment with PGE 2 reduced the amount of IFNc and TNFa secretion by NK cells. Likewise, in human NK cells, IFNc secretion was suppressed by PGE 2 in a dose-dependent manner [17] . Our data revealed that PGE 2 -mediated suppression of IFNc was primarily through the EP4 receptor. In CD4
? T cells, PGE 2 also inhibited IFNc production via EP4 receptor [18] . The mechanism controlling inhibition was through the cAMP-PKA pathway. Thus, EP4 is a common mechanism to negatively regulate IFNc in both CD4
? T cells and NK cells. PGE 2 inhibited NK cell production of TNFa through all three EP receptors. At 10 lM, the EP agonists Butaprost, Sulprostone, and PGE 1 -OH inhibited TNFa production by 51, 54, and 100 percent, respectively. In macrophages, evidence for inhibition of TNFa secretion through either the EP4 or EP2 receptors had been presented [19, 20] , but the inhibitory effects produced by the EP1/EP3 agonist that were observed were unanticipated. While we examined the effects of EP1 on TNFa, Spaziani et al. [21] examined changes in EP1 protein, EP1 mRNA, and PGE 2 concentrations in response to TNFa treatment in amnion WISH cell culture. They reported that treatment of WISH cells with TNFa increased EP1 expression and PGE 2 concentrations. In dental pulp cells, which are made of defense cells such as macrophages, granulocytes, and mast cells, TNFa stimulated PGE 2 production that in turn stimulated Ca 2? signaling. Therefore, it may be that inhibitory effects of EP1/EP3 agonist Sulprostone are through the EP1 receptor regulated by downstream Ca 2? signaling. In summary, we have shown NK cells express all four EP receptors ( Table 1) . The EP2 and EP4 receptors on NK cells, which are coupled to adenylyl cyclase activation, were found to be functional. PGE 2 predominantly inhibits NK cell migration and cytokine secretion through the EP4 receptor and, to a lesser extent, the EP2 receptor. NK cell mediated-cytotoxicity is negatively regulated through all four receptors. The results of several laboratories indicate that targeting the EP4 receptor may prevent metastatic disease, and the current study shows that targeting the EP4 receptor may prevent NK inhibition and have immunotherapeutic potential. Therefore, these findings support the further investigation of using specific antagonists of EP4 receptors to prevent disease progression via NK cell mechanisms. 
